← Leaderboards
Suryavathi Viswanadhapalli
University Of Texas Hlth Science Center
$873,997
Attributed
$1,747,994
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $709.1K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,747,994 · 1
By mechanism
R01$1,747,994 · 1
Top collaborators
- Ratna K Vadlamudi4 shared
Most similar at University Of Texas Hlth Science Center
Same institution · by research overlap
- Zhenming Xu$3,460,566
- Josephine A Taverna$1,600,331
- Behnam Ebrahimi$173,743
Others in their field
Other Rising Stars on “Combined Modality Therapy”
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Robert C Alexander · Banner Health$5,101,602
- Javier Caravaca · University Of California, San Francisco$3,728,080
- Xu Chen · University Of California, San Francisco$3,581,285
- Stuart Marcus · Sonalasense Inc$3,491,029
- Moustafa Gabr · Weill Medical Coll Of Cornell Univ$3,437,655
Research focus
Combined Modality TherapyComplementClustered Regularly Interspaced Short Palindromic RepeatsApoptosisAutocrine CommunicationBevacizumabAffinityAnabolismCancer EtiologyCancer PatientCancer RecurrenceCancer Stem CellCancer SurvivalCancer TherapyCancer CellCell ModelCessation Of LifeChemoresistanceChemotherapyChemotherapy And/Or RadiationClear CellClinically ActionableClinically SignificantComplex
Grant awards (4)
Development of new therapeutic approaches for endometrial cancer$709,125
R01 · FY2025 · CA · contact PI
Development of new therapeutic approaches for endometrial cancer$336,835
R01 · FY2024 · CA · contact PI
Development of new therapeutic approaches for endometrial cancer$347,471
R01 · FY2023 · CA · contact PI
Development of new therapeutic approaches for endometrial cancer$354,563
R01 · FY2022 · CA · contact PI